Dako Denmark A/S provides reagents, instruments, and software for cancer diagnostics to hospital and research laboratories worldwide. It offers pathology products, including reagents and antibodies; pharmacodiagnostic kits and pharmDx; staining instruments and instruments for image analysis; and systems where instruments, reagents, training, and service are integrated, which are used by pathologists for in vitro diagnostics to diagnose cancer and other chronic diseases on the basis of tissue samples. The company also provides flow cytometry products comprising reagents and accessories; instruments for flow cytometry; and systems that are used to analyze cells in blood and other fluids, and are employed in the diagnosis of leukemia, lymphoma, and other diseases. In addition, Dako Denmark A/S offers antibodies, which are used to measure the concentration of protein in blood, urine, and cerebrospinal fluid. It has collaboration with Genentech, OSI Pharmaceuticals, and Roche for the clinical development and application for a Premarket Approval Supplement and CE marking of EGFR pharmDx for use of the EGFR pharmDx test as a potential aid in the assessment of non-small cell lung cancer patients considered for treatment with Tarceva. The company was founded in 1966 and is headquartered in Glostrup, Denmark. Dako was acquired by Agilent Technologies in 2012.